Clinical trials: Metastatic or Unresectable Solid Tumors
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Cancer, Solid Tumor
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489369
- Testing
- Sym022
- Where
- 3 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Symphogen A/S
Claudin 18.2, Solid Tumor Malignancies
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on…
- Trial name
- NCT07704866
- Testing
- FG-B901, FG-M108
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Solid Tumors, Hematologic Cancers
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment.
- Conditions
- Solid Tumors, Hematologic Cancers, Metastatic Cancers
- Trial name
- AcSé (NCT02304809)
- Testing
- Vemurafenib
- Where
- France
- Volunteers
- 216 people
- Sponsor
- UNICANCER
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or…
- Trial name
- NCT06885034
- Testing
- Risvutatug Rezetecan
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 346 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Lung Cancer
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or…
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT05931445
- Testing
- e-PRO monitoring
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat and gemcitabine in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00243100
- Testing
- vorinostat, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
This randomized phase I trial is studying the side effects and best dose of O(6)-benzylguanine when given together with ifosfamide and to see how well it works compared to ifosfamide alone in treating patients with unresectable…
- Trial name
- NCT00086970
- Testing
- ifosfamide, O6-benzylguanine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Renal Cell Carcinoma, Non-small Cell Lung Cancer
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing…
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05769959
- Testing
- RO7515629, tocilizumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
This phase I/II trial identifies the side effects and best dose of pevonedistat when given together with pembrolizumab in treating mismatch repair deficiency (dMMR)/high-frequency microsatellite instability (MSI-H) solid tumor…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04800627
- Testing
- Pembrolizumab, Pevonedistat
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Soft Tissue Sarcoma
Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
- Trial name
- NCT03168061
- Testing
- NC 6300
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- NanoCarrier Co., Ltd.
Metastatic Malignant Neoplasm, Solid Neoplasm
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured…
- Conditions
- Metastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT02540876
- Testing
- Ilorasertib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Metastatic Solid Tumors
First in Human Study of M6223
The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) for both the every 2 weeks…
- Trial name
- NCT04457778
- Testing
- M6223, Bintrafusp alfa
- Where
- 4 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumors
BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors
This is a non-randomized，open-label，controlled multi-center Phase Ⅰ study to evaluate tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination with radiotherapy in patients with histologically or…
- Trial name
- BM201-1001 (NCT06368960)
- Testing
- Radiotherapy, BM201 injection
- Where
- China
- Volunteers
- 36 people
- Sponsor
- InnoBM Pharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum…
- Trial name
- NCT05205850
- Testing
- RC118-ADC
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Solid Tumor
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2.
- Trial name
- TACTIC-3 (NCT05862324)
- Testing
- TAC01-CLDN18.2
- Where
- 9 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Triumvira Immunologics, Inc.
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)